Switch to
More onapp

Medicamen Biotech Ltd

MEDICAMEQ
Health CarePharmaceuticals
SmallcapWith a market cap of ₹931 cr, stock is ranked 1,084
High RiskStock is 3.16x as volatile as Nifty
712.9523.20 (-3.15%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹931 cr, stock is ranked 1,084
High RiskStock is 3.16x as volatile as Nifty

Key MetricsEdit

PE RatioPE Ratio
62.46
PB RatioPB Ratio
6.36
Dividend YieldDiv. Yield
0.13%
Sector PESector PE
33.80
Sector PBSector PB
4.14
Sector Div YldSctr Div Yld
0.93%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

MEDICAMEN Biotech is engaged in manufacturing of pharmaceutical formulations.

Financial TrendFinancial statements 

2019202020212022126.26127.44113.47117.1712.0313.2912.1314.91
Revenue
Profit
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent NewsAll news 

Hmm, looks like data is unavailable here. Please come back after some time
See all news

Recent EventsAll events 

Board Meeting Intimation 
Announced OnJan 31, 2023

Pursuant to Regulation 29 read with Regulation 33 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( Listing Regulations ), we wish to inform you that a Meeting of the Board of Directors of Medicamen Biotech Limited ( the Company ) is scheduled to be held on Friday, February 10, 2023 at the registered office of the Company situated at 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019 to inter-alia, consider and approve the following business(s):1. The Un-audited Financial Results of the Company (Standalone and Consolidated) along with the Limited Review Report (Standalone & Consolidated) for the quarter and nine months ended on December 31, 2022. 2. Any other business with the permission of the chair.In this connection, please refer to our letter dated December 30, 2022, wherein it was informed that pursuant to the Company's Code of Conduct framed in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015 and amendments made there under, the trading window for dealing in the shares of the Company is closed for all designated persons of the Company from the January 01, 2023 and will open 48 hours after the said Financial Results are declared to the stock exchanges.This is for your information and record. | Download

Pursuant to Regulation 29 read with Regulation 33 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( Listing Regulations ), we wish to inform you that a Meeting of the Board of Directors of Medicamen Biotech Limited ( the Company ) is scheduled to be held on Friday, February 10, 2023 at the registered office of the Company situated at 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019 to inter-alia, consider and approve the following business(s):1. The Un-audited Financial Results of the Company (Standalone and Consolidated) along with the Limited Review Report (Standalone & Consolidated) for the quarter and nine months ended on December 31, 2022. 2. Any other business with the permission of the chair.In this connection, please refer to our letter dated December 30, 2022, wherein it was informed that pursuant to the Company's Code of Conduct framed in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015 and amendments made there under, the trading window for dealing in the shares of the Company is closed for all designated persons of the Company from the January 01, 2023 and will open 48 hours after the said Financial Results are declared to the stock exchanges.This is for your information and record. | Download

Loss of Share Certificates 
Announced OnJan 24, 2023

Medicamen Biotech Limited has informed the Exchange about Loss of Share Certificates | Download

Medicamen Biotech Limited has informed the Exchange about Loss of Share Certificates | Download

Cash Dividend 
Ex. DateSep 19, 2022

Final • Div/Share: ₹ 1

See all events